Voyageur Pharmaceuticals Ltd (VM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VM) has a cash flow conversion efficiency ratio of -0.295x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-369.98K ≈ $-267.64K USD) by net assets (CA$1.25 Million ≈ $906.00K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Voyageur Pharmaceuticals Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Voyageur Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Voyageur Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Voyageur Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
0.736x |
|
Birlik Mensucat Ticaret ve Sanayi Isletmesi AS
IS:BRMEN
|
25.838x |
|
Avicanna Inc
TO:AVCN
|
-0.075x |
|
Finlay Minerals Ltd
V:FYL
|
0.037x |
|
Big Rock Brewery Inc.
TO:BR
|
-0.021x |
|
Hampton Financial Corp
V:HFC
|
-1.435x |
|
WAPS Co. Ltd
KQ:196700
|
0.023x |
|
Gaxos.ai Inc
NASDAQ:GXAI
|
-0.163x |
Annual Cash Flow Conversion Efficiency for Voyageur Pharmaceuticals Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Voyageur Pharmaceuticals Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Voyageur Pharmaceuticals Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-11-30 | CA$1.25 Million ≈ $906.00K |
CA$-2.89 Million ≈ $-2.09 Million |
-2.310x | -243.80% |
| 2024-11-30 | CA$449.96K ≈ $325.49K |
CA$-302.29K ≈ $-218.67K |
-0.672x | +2.69% |
| 2023-11-30 | CA$1.44 Million ≈ $1.04 Million |
CA$-991.25K ≈ $-717.06K |
-0.690x | +41.17% |
| 2022-11-30 | CA$1.46 Million ≈ $1.06 Million |
CA$-1.72 Million ≈ $-1.24 Million |
-1.174x | -35.22% |
| 2021-11-30 | CA$1.91 Million ≈ $1.38 Million |
CA$-1.65 Million ≈ $-1.20 Million |
-0.868x | +2.33% |
| 2020-11-30 | CA$306.33K ≈ $221.60K |
CA$-272.19K ≈ $-196.90K |
-0.889x | -5.05% |
| 2019-11-30 | CA$754.09K ≈ $545.50K |
CA$-637.81K ≈ $-461.38K |
-0.846x | +11.07% |
| 2018-11-30 | CA$515.68K ≈ $373.04K |
CA$-490.45K ≈ $-354.79K |
-0.951x | -113.60% |
| 2017-11-30 | CA$-89.24K ≈ $-64.55K |
CA$-624.24K ≈ $-451.56K |
6.995x | +13473.35% |
| 2016-11-30 | CA$670.46K ≈ $485.00K |
CA$-35.07K ≈ $-25.37K |
-0.052x | +94.07% |
| 2015-11-30 | CA$80.07K ≈ $57.92K |
CA$-70.65K ≈ $-51.11K |
-0.882x | -204.17% |
| 2014-11-30 | CA$81.56K ≈ $59.00K |
CA$-23.66K ≈ $-17.11K |
-0.290x | +6.71% |
| 2013-11-30 | CA$176.02K ≈ $127.33K |
CA$-54.73K ≈ $-39.59K |
-0.311x | -3070.28% |
| 2012-11-30 | CA$221.34K ≈ $160.12K |
CA$2.32K ≈ $1.68K |
0.010x | +106.87% |
| 2011-11-30 | CA$185.00K ≈ $133.83K |
CA$-28.19K ≈ $-20.39K |
-0.152x | -- |
About Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more